UK headquartered biotech firm Adaptimmune Therapeutics’ (Nasdaq: ADAP) shares were up 11.57% at $7.52 mid-morning today on the news that GlaxoSmithKline (LSE: GSK) has exercised its option to exclusively research, develop and commercialize its NY-ESO SPEAR T-cell therapy. GSK edged up 0.35% to £15.11.
On the exercise of this option and transition of the program, UK pharma major GSK will assume responsibility for all development, manufacturing and commercialization activities for the asset.
Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program (GSK3377794). In 2015, GSK divested its oncology assets in a swap with Novartis, but said it would continue R&D activity in the oncology arena though not necessarily commercialize resultant products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze